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Monoclonal antibodies (Mab) 1 against cell surface constituents have the poten- 
tial  to  become  powerful  tools  in  both  diagnosis  and  therapy  of  malignant 
neoplastic diseases (1, 2) and have already proven so in leukemias and lymphomas 
(3-5).  Most of the reported  Mab against human malignant cells are of murine 
or rat  origin  (6,  7).  The  rodent hybridoma system has the advantage of high 
fusion frequencies,  high antibody production,  and access to optimally antigen 
primed B  lymphocytes. However,  it is conceivable that the antigenic spectrum 
recognized across a xenogeneic barrier (e.g., mouse-recognizing human antigens) 
is more narrow than across an allogeneic barrier. 
The importance of human monoclonal antibody technology in cancer biology 
is based  on the possibility, by this technique of addressing the long prevailing 
question (8) in tumor immunology: Do human beings recognize and react against 
specific antigens on  autochthonous tumors? Analysis of the autologous tumor 
reactivity of sera from patients with melanoma (9-1 1), astrocytoma (12),  renal 
cancer (13), and leukemia (14) revealed three classes of antigens. Some antigens 
are expressed only on autologous tumor cells, some on autologous and allogeneic 
tumors and on a  restricted range of normal cells, and some are distributed on a 
broad range of normal and malignant cells. It is the first two types of antigens 
that are of most importance in tumor immunology, because antibodies against 
these antigens can be expected to have value in several areas of cancer biology 
and perhaps also in the clinical management of neoplastic diseases. 
Human hybridoma technology was recently used to study the humoral immune 
reactions of melanoma patients against their autologous tumors (15). A  number 
of human  Mab were obtained.  Most reacted with intracytoplasmatic structures 
of the malignant cells. 
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l Abbreviation,s used i1~ this paper." Ab, antibody; ALL, acute lymphoblastic  leukemia; AML, acute 
myeIoid leukemia; DMSO, dimethyIsutfoxide;  EBV, Epstein-Barr virus; ELISA, enzyme-linked  im- 
munosorbent assay; FAB, French-American-British;  FACS, fluorescence-activated  cell sorter; FCS, 
fetal calf serum; FITC, fluorescein  isothiocyanate;  HAT, hypoxanthine-aminopterin-thymidine;  HT, 
hypoxanthine-thymidine; lg, immunoglobulin; Mab, monoclonal antibodies; O.D., optical density; 
PBL, peripheral blood lymphocytes;  PBS, phosphate-buffered  saline; PEG, polyethylene  glycol;  PMC, 
peripheral mononuclear cells; PWM, pokeweed mitogen. 
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We here report the derivation and characterization  of a  monoclonal  human- 
human hybridoma antibody with high specificity for human leukemia cells. 
Materials and  Methods 
Fusion Partners and Fusion Procedures.  Peripheral blood mononuclear cells (PMC) from 
seven patients with acute myeloid leukemia (AML) in clinical remission were used in nine 
fusion experiments. PMC from each patient were separated from erythrocytes, granulo- 
cytes,  and  dead  cells  on  a  Ficoll-hypaque  gradient  and  subsequently  stimulated  with 
pokeweed mitogen (PWM; Gibco Laboratories, Grand Island, NY; final dilution 2.5/~g/ 
106 cells/ml) in RPMI-1640 medium with  10% fetal calf serum (FCS) and supplemented 
with  10  -4 M hypoxanthine,  10 -7 M aminopterin, and 10 -6 M thymidine (HAT medium). 
Dead cells and debris were removed from the cultures by centrifugation on Ficoll-hypaque 
5 d after addition of PWM, viable cells were washed twice in phosphate-buffered saline 
(PBS), and  1-5 x  107 cells fused with the malignant fusion partner at a cell ratio of 1:1. 
The malignant fusion partner was in all experiments a human B lymphoma, designated 
RH-L4, that produces, but does not secrete IgG(k) (15).  Fusion procedures have been 
described in more detail elsewhere (15).  Briefly, lymphocytes and lymphoma cells were 
fused in 0.2  ml 30%  (wt/vol) polyethylene glycol (tool wt  1,000; J.  T. Baker Chemical 
Co.,  Phillipsburg,  NJ),  washed  twice  in  RPMI-1640  medium  and  seeded  into  96-well 
plates at a concentration of 2-4  x  105 cells per well  in  RPMI-1640 medium with  10% 
FCS.  Most of the culture medium was replaced with HAT medium 1-2 d later. The cells 
were grown for 14-18 d in HAT medium that eventually was replaced by HT medium. 
Further  cultivation  and  expansion  of a  number  of human  hybridomas  indicated  that 
highest stability and  growth  rate  was obtained by maintenance  of the cultures  in  HT 
medium instead of RPMI-1640 medium. The hybridoma cell line designated aml-18 has 
now been maintained in culture for 24 months and still grows best in HT medium. 
Antibody Assays.  All supernatants were analyzed for human #-, 3'-, K-, and ),-chains  by 
enzyme-linked immunosorbent assay (ELISA) and  for reactivity to  AML cells  by cell 
binding ELISA (16).  The latter assay was done with a mixture of AML cells from eight 
different patients. The cells were seeded into 96-well plates, precoated with poly-L-lysin, 
with 2  x  105 cells per well.  Alkaline phosphatase-conjugated rabbit anti-human Ig final 
dilution  1:2,000; (DAKO, Denmark) was used as second step reagent. O.D. values were 
<0.150  for  negative  controls  in  all  experiments.  O.D.  values  of  0.300-0.500  were 
considered weakly (+) positive, values between 0.500-1.000  were rather strongly (++) 
positive, and O.D. values > 1.000 indicated very strong (+++) reactivity. Controls included 
cells incubated with (a) only RPMI-1640 medium, and (b) with only second step antibody 
(peroxidase-conjugated rabbit anti-human Ig). The highest O.D. values from these groups 
were used as control values. Moreover, binding to cell surface components on viable AML 
cells was analyzed by fluorescence-activated cell sorter (FACS). The 2  ×  10  ~ AML cells 
were incubated with 0.2 tA Ig-containing supernatant (diluted  1:1  in PBS) for 45 rain at 
4°C, washed twice in  PBS, and incubated in 0.1  tA FITC-conjugated rabbit anti-human 
Ig (final dilution  1:20-1:50,  Tago, Burlingame, CA) for 30 rain at 4°C. The cells were 
finally washed three times in PBS and analyzed. A 25-50 channel shift in fluorescence on 
a  linear scale was considered weak (+) reactivity, 50-100 channel shift indicated rather 
strong  (++)  reactivity, and  a  shift  >100  channels  was  considered  very  strong  (+++) 
reactivity. Controls included  unstained  cells  and cells only incubated with  FITC-conju- 
gated rabbit anti-human  Ig. The latter (the  highest  fluorescence signal) was used as a 
control. 
Hybridoma cultures secreting Ig with  high  reactivity to AML cells  were cloned  by 
limiting  dilution  in  96-well plastic  plates  with  human  monocytes as  feeder  cells  in  a 
concentration of 104-5 x  104per well. Procedures for isolation of monocyte feeders and 
details  of cloning  were  described  recently (17).  Supernatants  from cloned  hybridoma 
cultures were screened for Ig content and reactivity to AML cells by the same procedures 
as  the  initial  culture  fluids.  Hybridomas that  secreted  Ig with  reactivity to  AML cell 
surface constituents were subsequently tested for reactivity against lymphocytes, mono- OLSSON  ET AL.  539 
cytes, and erythrocytes of the patient, who provided the lymphocytes for fusion. Lack of 
binding to these cells resulted in further expansion of the culture that subsequently was 
analyzed for reactivity against a large panel of normal and malignant cells of both human 
and animal origin. 
Cell Panel to Define Antibody Specificity.  Human tumor cell lines:  HL-60 (promyelocytic 
leukemia; 18), K56~ (erythroleukemia; 19), U-937 (histiocytic lymphoma; 20), RH-L4, (B 
lymphoma;  15),  RH-SLC-L11 (squamous cell lung carcinoma; 21),  RH-SCC-L10 (small 
cell carcinoma; 21), U-266 (human myeloma; 22), Molt-4 (T cell leukemia; 23), DAUDI 
(Burkitt lymphoma; 24), and human foreskin fibroblasts. All  lines were maintained in 
RPMI-1640 medium with  10-15% FCS and 0.3% L-glutamine. Other human cell types 
included granulocytes, monocytes, lymphocytes, normal bone marrow aspirates, erythro- 
cytes, and  thymocytes (prepared from thymus biopsies of patients  undergoing cardiac 
surgery). Adherent cell lines were prepared for analysis as follows: the cells were detached 
from the  plastic by trypsinization for  10-15  min at  37°C,  washed twice in  PBS, and 
cultivated for 24-48 h in RPMI-1640 with 10% FCS in a plastic vessel placed on a rocking 
platform, thereby preventing reattachment of the cells,  but allowing the cells to regain 
the cell surface attributes they had before trypsinization. 
Leukemia  Samples.  Peripheral  blood from patients  with  cytologically verified acute 
leukemia was obtained before onset of cytoreductive treatment and classified according 
to the French-American-British (FAB) classification (25). PMC from samples with leukemia 
cells were purified by centrifugation on a Ficoll-hypaque gradient, frozen (minus 1 °C per 
minute) in RPMI-1640 medium with 30% FCS and 10% DMSO at a concentration of 2 
×  107 cells/ml and stored in  liquid nitrogen.  Cell viability was  80-90%  as judged by 
trypan blue dye exclusion. Differentials of thawed cells were comparable to those before 
freezing. A total of 63 different leukemia samples were analyzed. AML cell samples often 
contained cells that varied largely in size, which is reflected in the scatter signal  on the 
FACS. Analysis was done for each sample on medium (~10-15 #m) and large (15-30 #m) 
sized cells by gating on first the medium-sized cells and subsequently the large cells (Fig. 
1). The content of leukemia cells in each of these two fractions was estimated from May- 
Griinwald-Giemsa stained cytocentrifuge preparations of cells  that  were isolated from 
each fraction by FACS. This procedure was only applied in samples with <70% leukemia 
cells. 
Complement-dependent Antibody-mediated Cytotoxicity Assay.  One human monoclonal an- 
tibody (ami-18) was assayed in a conventional microcytotoxicity assay (26) using  1 #1 of 
antibody,  l0  s target cells  suspended  in  1 #1  RPMI-1640,  and  1 #1  complement.  The 
complement had to be selected carefully, as most conventional rabbit complement sources 
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FIGURE  l.  Typical scatter signal profiles of AML cell populations. Bars indicate gates for 
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result in nonspecific cytolysis. However, after examination of a number of different types 
of complement, a mixture of V~ rabbit serum and % human  AB-serum was found to be 
applicable. Antibody absorption with cells was performed as described by others (9). 
Antibody Characterization.  The  monoclonality of the hybridoma cultures  was assured 
by 2D-analysis of [35S]methionine-labeled Ig products from the hybridomas. 2 ×  106 cells 
were cultivated for 18 h in RPMI-1640 medium (without methionine), but supplemented 
with 50 uCi [35S]methionine.  Supernatants  were harvested and  Ig products precipitated 
with rabbit anti-human  Ig, and analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide 
gel electrophoresis, or by isoelectric focusing followed by SDS (2D-electrophoresis) (27). 
The isotype of the Mab was determined  by ELISA (16) with antibodies with specificity 
for the heavy (u, 3') and light (K, 2,) chains of human Ig. Fab-fragments were prepared by 
brief papain digestion (28), isolation on a Sephadex G-100 and freed from contamination 
of Fc-fragments and intact IgG by passage through a protein A-Sepharose column. The 
Fab-fragments were FITC conjugated by standard procedures. 
Results 
Fusion Frequency, Hybridoma Yield, and Initial Screening.  Nine fusions with PMC 
from patients  with  AML in partial  or complete  remission  resulted  in  521  wells 
with  hybridoma  growth  out of 1436 wells seeded (Table  I).  Ig production  was 
detected in  305 of the 521  wells, but only 26 wells contained  supernatants  that 
reacted  with  AML  cells.  Specificity  analysis  showed  (Table  II)  that  only  five 
TABLE  I 
Hybridoma Yield, and Ig Production in Nine Fusions with RH-L4 Lymphoma Cells with 
Peripheral Monoclonal Cells  from AML Patients in Partial or Complete Remission 
No fusions  No. supernatants  with 
with hybrid  No, wells  with hybrids/total  No. wells  with lgG produc-  No. wells  with IgM pro-  lg-binding  to AML 
growth*/To-  no. wells  tion/Total no. wells  with  duction/Total no. wells  cells/Total  no. wells 
tal no. fu-  hybrids  with hybrids  with Ig 
sions 
7/9  43/164;97/140;  18/43;37/97;  10/43;17/97;  2/28;5/54; 
55/210; 82/278;  40/55; 42/82;  6/55; 12[82;  7/46; 0/42; 
110/280; 105/244;  381110; 35/105;  15/110; 17/105;  1/38; 11/35; 
29/120;  11129;  7/20;  09/28; 
* No.  wells  with hybrid growth and lg production was scored ~30 d and ~50 d after fusion. The maximal  values of these two 
enumerations  are indicated. 
TABLE  II 
Reactivity Pattern 0f26 Ig-Containing Supernatants  that Bind to AML Cells as Assayed by 
ELISA and~or FACS 
No. supernatants 
reactive with 
PMC from the pa-  No. supernatants  No. supernatants  No, supernatants  No. supernatants 
reactive with  reactive with 
tient from whom  PMC from nor-  foreskin fibro-  reactive with ma-  reactive with only 
lymphodytes for  mal individuals*  blasts  lignant cell lines  0  AML samples 
fusion were ob- 
tained* 
6  11  3  16  5 
* The  reactivity of the  supernatants was analyzed 60-90  d  after fusion.  Both  ELISA and  FACS 
analysis was used to assess the reactivity pattern. The numbers indicate positive reaction in one or 
both of these two types of analysis. 
* Tested on PBL from  10 individuals. 
The cell lines were: RH-L4, SCC-L10, SCL-L1 1. OLSSON ET  AL.  541 
hybridoma cultures  bound with  high  specificity to AML cells.  However, upon 
continuous  expansion  of these  five  cultures,  only  one  proved  stable  both  in 
growth  properties  and  Ig  production.  The  four  unstable  cultures  all  lost  Ig 
production activity and subsequently growth activity. The fifth hybridoma cul- 
ture, designated aml-18, has now been stable for >2 years for growth, but rather 
frequent recloning (every 3-4 months) has been necessary to maintain  Ig pro- 
duction. 
Characteristics of the Aml-18 Antibody.  The aml-18 hybridoma cells secreted the 
Ig products (% ~c) of the parental  RH-L4 lymphoma and a  new "r-chain  and  K- 
light chain. 5-15 #g Ig of which < 1 #g is of parental RH-L4 Ig type are produced 
by 106 cells per 24 h.  Some of the  Ig molecules are permutated,  but ~80%  of 
the Ig in the supernatant  was the  Mab of interest.  The ami-18 antibody binds 
complement  and  can  be  used  in  a  cytotoxicity assay.  Aml-18  hybridoma  cells 
were injected subcutaneously into nude mice (5-10 ×  106 cells) mixed with 2 × 
106 human foreskin fibroblasts. 6 of 10 mice got subcutaneous tumors of which 
4 were successfully converted into ascites tumors upon 2-5 passages into other 
nude mice. However, ascites from three of these tumors did not have significantly 
increased antibody titer compared with culture supernatants.  The fourth tumor 
gave in some aspirates higher  titers,  but not in a  predictable and reproducible 
way.  Further  attempts  to  grow aml-18  cells as  ascites  tumors  were  therefore 
abandoned. 
Antibody Specificity.  Further details of the results of the fusion from which aml- 
18 developed are  outlined  in  Table  III.  7  of the  11  hybrid supernatants  that 
initially reacted with AML cells were not positive in the first ELISA test for Ig 
production. This reinforces the insufficiency of an assay for Ig production as the 
only basis for initial  selection of hybrids.  Screening on a  panel  of normal  cells 
(Table IV) revealed that 6  of the  11  hybrids could be of potential interest and 
were  subsequently  cloned.  Further  screening  of the  cloned  cultures  clearly 
indicated  that  only  the  aml-18  hybridoma  had  high  specificity for  AML cells 
(Table V). 
Analysis of aml-18 reactivity against a panel of cells (Table V) showed that the 
antibody is highly specific for human leukemia cells. Weak binding was found to 
normal human bone marrow cells, when undiluted supernatants were used. This 
reactivity  was  eliminated  in  a  titer  1:8  (Fig.  2)  that  gave  binding  to  human 
leukemia cells. Moreover, Fab fragments of the ami-18 antibody did not bind to 
TABLE III 
Further Details of Screening Results  from the Fusion  from Which the aml-18 was Obtained 
No. supernatants 
No. supernatants  No. supernatants  with  reactivity to 
reacting with  AML cells/posi- 
with Ig  AML cells  tive for Ig con- 
tent 
3 wk after fusion  19  2  2/1 
6 wk after fusion  52  11  11/4 
Ig-type of 11 su- 
pernatants react- 




Ig production and Ig subtypes  were determined by ELISA. Reactivity  with AML cells  was determined 
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TABLE  IV 




AML-3  AML-5 AML-II  AML-17 AML-18 AML-23 AML-24 AML-32 AML-36 AML-41 AML-60 
PMC  +~t  Neg  Neg  +  Neg  +  +  +  +  Neg  + 
Erythrocytes  Neg  +  Neg  +  Neg  Neg  +  Neg  Neg  +  + 
Fibroblasts  Neg  Neg  +  +  Neg  +  +  Neg  +  Neg  + 
Bone marrow  +  +  Neg  +  Neg  +  +  +  +  +  + 
Thymocytes  Neg  Neg  Neg  Neg  Neg  +  +  +  Neg  +  + 
Platelets  +  Neg  +  Neg  Neg  Neg  +  Neg  +  +  Neg 
Mouse  spleen  Neg  Neg  +  Neg  Neg  Neg  Neg  +  +  Neg  + 
mononuclear 
cells 
* All cells were analyzed with ELISA and FACS for reactivity with supernatants, except for platelets that were analyzed only by 
FACS. 
* + indicates significant  binding of the antibody as detected by ELISA and/or  FACS, O,D. >0.300 was considered significantly 
increased in the EL1SA (background <0.150), and a fluorescence  channel shift >25 as compared with cells only incubated with 
FITC-conjugated  second step antibody in FACS  analysis. 
TABLE  V 
Reactivity Against a Panel of Normal and Malignant Cells of lg in 
Supernatant from the Cloned aml-18 Human Hybridoma 
Cell type* 
aml-18 antibody dilution  Fab -  FITC 
1:2  1:8  1:2  1:8 
HldlRall 
AML  ++~  ++  ++  ++ 
ALL  +S  Neg  +  Neg 
RH-SCC-L 10  Neg  Neg  Neg  Neg 
RH-SCL-L 11  Neg  Neg  Neg  Neg 
HL-60  ++  ++  ++  ++ 
RH-L4  Neg  Neg  Neg  Neg 
K562  +  Neg  +  Neg 
DAUDI  Neg  Neg  Neg  Neg 
U-266  Neg  Neg  Neg  Neg 
U-937  Neg  Neg  Neg  Neg 
Molt-3  Neg  Neg  Neg  Neg 
Fibroblasts  Neg  Neg  Neg  Neg 
Erythrocytes  Neg  Neg  Neg  Neg 
PMC  Neg  Neg  Neg  Neg 
Granulocytes  (+)§  Neg  Neg  Neg 
Normal bone marrow  (+)  Neg  Neg  Neg 
Platelets  Neg  Neg  Neg  Neg 
l'Vlouse 
Spleen cells  Neg  Neg  Neg  Neg 
AKR leukemia cells  Neg  Neg  Neg  Neg 
Fibroblasts  Neg  Neg  Neg  Neg 
Bone marrow  Neg  Neg  Neg  Neg 
* Analyzed by ELISA  and  FACS,  except  platelets  that  only were  analyzed by 
ELISA. 
~; +  and ++ indicate significant binding as detected by EL1SA and/or FACS. 
(+) indicates O.D.  values of 0.200-0.300  in ELISA and/or a  channel shift on 
10-25 on the fluorescence signal. OLSSON  ET AL.  543 
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FIGURE 2.  Cytotoxic activity ofaml-18 hybridoma antibody on an AML cell population with 
>90% myeloid leukemia cells and on normal myeioid bone marrow cells; (O) aml-18 Ab against 
AML cells (1) aml-18 Ab against normal bone marrow cells;  (&) aml-18 Ab absorbed  with 
normal bone marrow cells (BM); (0) ami-18 Ab absorbed with myeioid leukemia ceils. 
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FIGURE 3.  FAGS  analysis of an AML sample (>80% AML cells) stained with aml-18 Ab in a 
dilution of I/z6. Scatter signal is seen on left histogram and the gating indicated by markers. 
Fluorescence signal (right  histogram) shows control  sample (I;  stained only with FITC- 
conjugated rabbit anti-human Ig in a dilution 1:20) and the sample stained with aml-18 Ab 
and subsequently F1TC-conjugated rabbit anti-human Ig (I/). 
normal  bone  marrow  cells  (Table  V).  Fig.  3  shows  the  size  of  the  FACS 
fluorescence signal  that  is typically obtained by aml-18  (diluted  1:16),  when  it 
binds to AML cells. 
63  leukemia  samples  were  analyzed  with  aml-18  and  the  reactivity pattern 
related to the FAB classification of these leukemias (Table VI). 24 samples (40%) 
were positive, including two of four acute lymphoblastic leukemia (ALL) samples. 
No correlation in frequency of positive samples and the FAB classification was 
seen.  No morphological differences were seen between cells that bind the ami- 
18 antibody compared to those that were negative for the antibody. Estimation 
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TABLE  VI 
Reactivity Pattern of HuMab-aml-18  to a Panel of Leukemia Cell 
Samples 
No samples reactive with aml-18 
Types of leukemias*  mab/Total no. samples 
AML-M1  3/7 
AML-M2  8/21 
AML-M3 
AML-M4  5/9 
AML-M5  6/17 
ALL  2/4 
AUL  0/2 
AL, total  24•60 
Others 
CMML  0/1 
PCL  0/1 
L1  +  M4  0/1 
Total  24/63 
* ALL,  acute  lymphoblastic  leukemia;  AML,  acute  myeloid  leukemia; 
AUL, acute  unclassifiable leukemia; CMML,  chronic myelomonocytic 
leukemia; PCL, plasma cell leukemia; LI + M4, mixed type of leukemia. 
TABLE  VII 
Percentage of Leukemia Cells Reactive with aml-18 in Positive AML 
Samples 
Percentage of 
Leukemia type  reactive cells* 
No. of reactive samples 
+  ++  +++ 
% 
AML-M 1 (Total:7) 
Mean  22  2  5 
Range  11-43 
AML-M2 (Total:21) 
Mean  44  9  10 
Range  21-78 
AML-M4 (Total'9) 
Mean  50  5  4 
Range  26-86 
AML-M5 (Total:l 7) 
Mean  33  3  13 
Range  15-53 
ALL (Total:4) 
Mean  37  2 
Range  10-64 
* Taken from the gated population with most leukemia cells (if more than 
one). 
* Reactivity grading as described in Materials and Methods. OLSSON ET AL.  545 
a pronounced intratumoral heterogeneity with many leukemia cells being nega- 
tive for the aml-18 epitope within the leukemia cell populations that were scored 
positive for aml-18 (Table VII). 
Discussion 
Immortalization of human  B  lymphocytes by fusion  with human  malignant 
lymphoma celis/myeloma cells/lymphoblastoid cells, EBV transformation or fu- 
sion with  mouse myeloma cells are all  feasible approaches to produce human 
Mab (16, 29-35). Each of these techniques all have drawbacks like chromosomal 
instability, low Ig secretion, and low hybrid yield, which are some of the main 
reasons wby production  of human  Mab  still  is a  more laborious and  tedious 
process than the mouse hybridoma antibody production.  In addition,  in vitro 
antigen-priming systems are required for a  broad  applicability of the  human 
hybridoma technology, but  these techniques are not yet developed to a  stage 
that allows both primary and secondary immune response in vitro to a  broad 
and predefined antigenic spectrum. 
The possibility of dissecting the antigenic repertoire recognized by human B 
cells on different biological components, including human tumors, is one of the 
major biological aspects of human monoclonal antibody technology. In the case 
of human tumors, it allows one of the basic questions in cancer immunology to 
be addressed, whether human malignant cells express antigens that are recog- 
nized as foreign by the autologous host (8). A few studies on human Mab reactive 
with antigens on tumor cells have been reported (15, 36-38), but none of these 
antigens seems specific for neoplastic cells. It was further found in one of these 
studies (15)  that  melanoma patients  mostly react with intracellular structures, 
rather than cell surface constituents. This probably reflects the high and abnor- 
mal cell decay rate of malignant tumors, which exposes the autologous host to a 
number of intracellular structures that  are not  normally encountered by the 
immune system of healthy persons. 
Mab  are already used in  diagnosis of human acute lymphoid leukemias.  A 
similar approach has not yet been successful in AML because attempts to generate 
Mab  against  defined subsets  of myeloid cells  have  encountered considerable 
difficulties.  Mouse  Mab  with  high  specificity  for  myeloid cells  seem  almost 
invariably also to bind to monocytes (or subsets) (39-41), and this hampers the 
use of such Mab as diagnostic tools in AML. The possibility that some human B 
lymphocvtes in AML patients recognize antigens that are expressed on some or 
all the leukemia cells, but not on the normal cell populations in the patients was 
the  logistic  background  for  our  attempts  to  generate  human  Mab,  because 
immortalization of such iymphocytes could lead to generation of Mab with high 
specificity for leukemia cells. 
PMC from AML patients were used as B lymphocyte source in all experiments. 
The patients were in partial or complete remission, because the hybrid yield was 
found to be extremely low, when PMC from patients with circulating leukemia 
cells were used.  However, the hybrid yield was also very low with PMC  from 
patients in remission compared to a mouse-mouse fusion with optimally antigen- 
primed lymphocytes. Cocuhivation in vitro of PMC with AML cells for 3-10 d 
did not result in improved hybrid yield, rather the opposite (data not shown). 546  HUMAN  MONOCLONAL  ANTIBODY  AGAINST  LEUKEMIA  CELLS 
Thus,  only one  hybridoma  (aml-18)  out of 305  had  acceptable specificity for 
leukemia  cells,  which  clearly  indicates  the  urgent  need  for  improved  in  vitro 
antigen-priming  systems. 
The aml-18 Mab bound to ~38% of the leukemia samples that were analyzed, 
but not to a variety of other malignant or normal human cells. The weak reaction 
with  normal  bone  marrow  could  easily  be eliminated  by titration.  As  FITC- 
conjugated Fab fragments of the aml-18 antibody did not bind to normal cells, 
we consider  the  weak binding  of aml-18  antibody to be nonspecific reactivity. 
This is substantiated by recent experiments on the characteristics and modulation 
pattern  of the  antigen  recognized  by  the  aml-18  antibody  (Olsson  et  al.,  in 
preparation).  These experiments  indicate  that  the antigen  is a  cellular protein 
with a Mr ~58,000, and Western-blotting experiments have failed to demonstrate 
its presence on 11 samples of normal bone marrow cells. It is also of interest that 
the  aml-18  Mab  does  not  bind  to  murine  malignant  cells,  including  mouse 
leukemia.  The  antibody  is  not specific for AML,  as two samples of ALL also 
were positive. The diagnosis of ALL was primarily based on cytology. All AML 
were FAB classified, and no correlation between FAB classification and aml-18 
reactivity  was  seen.  Fluorescence  microscopy showed  that  the  antigen  can  be 
detected only on the cell surface (ring fluorescence). 
Each  individual  leukemia  sample  was found  to contain  variable amounts  of 
aml-18 positive cells. Intratumoral  antigenic heterogeneity was thus pronounced 
in respect to the ami-18 epitope in line with previous studies on other antigens 
expressed  on  murine  (42)  or  human  (43,  44)  leukemia  cells  and  on  human 
melanoma cells (45). The variability in antigen expression in respect to both the 
antigen  density as  evaluated  by FACS  analysis,  and  the  existence  of antigen- 
negative leukemia cells in a sample with antigen-positive cells, suggests that the 
leukemic cells may be phenotypically diversified in respect to a number of other 
features.  This diversification is not reflected in the FAB classification and may 
be one reason for the  lack of success in the many attempts to generate  mouse 
antibodies specific for AML. 
The  reactivity  pattern  of aml-18  does  not  conform  to  any  known  antigen 
system  or  differentiation  pathway.  The  biological  function  of the  antigen  is 
unknown,  but  its  high  specificity  for  leukemia  cells  suggests  that  the  gene 
encoding  for  the  antigen  is associated with  genes directly  responsible  for  the 
leukemic  behavior.  The  gene  coding  for the aml-18  antigen  is therefore  now 
being characterized and searched for in both leukemic and normal bone marrow 
cells. 
Summary 
Human-human  hybridoma  technology  was  used  to  immortalize  human  B 
lymphocytes from  patients  with  acute  myeloid  leukemia  (AML)  to  study  the 
antigenic repertoire of the humoral immune response against the patients'  own 
leukemia cells and against leukemic cells from other patients.  Nine fusions were 
done with lymphocytes from seven AML patients,  and all with the human  RH- 
L4 B lymphoma line as malignant  fusion partner.  A  total of 505  Ig-producing 
hybrids were obtained.  26 reacted with cell surface components on AML cells, 
but  21  were  found  not  to  be  specific  for  leukemia  cells,  when  screened  for OLSSON ET  AL.  547 
reactivity against a  panel  of normal  and  malignant cells of both  human and 
murine origin.  Five hybridomas secreted  Ig  with  high  specificity for human 
leukemia cells,  but only one hybridoma culture, aml-18, was stable in respect to 
Ig-production  and  growth  upon  repeated  clonings  and  expansion  in  liquid 
cultures. A method was developed to grow human hybridomas as ascites tumors 
in nude mice, but the ascites fluid did not contain increased amount of antibody. 
The reactivity of the ami-I8 antibody (%  ~) was analyzed against samples of 
mononuclear cells from peripheral blood of 63 patients with leukemia and with 
cytologically  verified leukemia cells in the blood. 22 of 54 AML samples reacted 
with aml-18. The reactivity pattern was not correlated to any categories of the 
French-American-British (FAB) classification; two of four ALL were positive. 
Moreover, a pronounced intratumoral antigenic heterogeneity in regard to atol- 
l 8 reactivity was seen and indicates a high degree of diversity in the immunolog- 
ical phenotype within individual AML cell populations. 
The study demonstrates that some patients with AML generate an immune 
response against their autologous malignant cells,  and that the antigenic deter- 
minant in the case of aml-18 is also expressed specifically on leukemic cells from 
other patients. 
The excellent technical assistance of Mrs. H. Kronstr~m and Mr. J. P. Stenvang is highly 
appreciated. 
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